More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin...

Related Keywords

United States ,New York ,American ,Mark Genovese ,Joe Fletcher ,Rachel Hoffmeyer ,Eli Lilly ,Andrew Alexis ,Facebook ,Immunology Development At Lilly ,Clinical Development Program ,Department Of Dermatology At Weill Cornell Medicine ,Linkedin ,American Academy Of Dermatology Conference ,Presbyterian Weill Cornell Medical Center ,American Academy Of Dermatology ,Instagram ,Exchange Commission ,American Academy ,Clinical Dermatology ,Vice Chair ,Weill Cornell Medicine ,Weill Cornell Medical Center ,African American ,American Indian ,Alaska Native ,Immunology Development ,Eczema Area ,Severity Index ,Global Assessment ,Pruritus Numeric Rating Scale ,Clinical Development ,Private Securities Litigation Reform Act ,United States Securities ,Dermatol Ther ,Dominant Disease ,Greater Molecular Heterogeneity Compared ,Eli Lilly And Company ,